Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.

Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognoses to patients having IFN?-induced disorders.

Abstract: The present invention encompasses miRNA profiles and type-I IFN/IFN?-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders.

Abstract: The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles.

Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.

Abstract: The present invention encompasses type-1 IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.

Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Abstract: A decorative illumination includes an illumination string and a baseplate. The baseplate is provided with laser film. The illumination string fits inside a lamphole, and the lamphole is a through hole that penetrates the baseplate and laser film. The baseplate is made form plastic film material. In addition, there is a support frame on the other side of the laser film opposite to the base plate, and the illumination string is inside the support frame and fitted in the lamphole. The illuminations in accordance with the present invention provide advantages of simple structure and aesthetic appearance that can beautify the environment and provide perfect night lighting effect, which can be used for decoration, beautifying the environment, etc.

Abstract: A kind of soft plastic iridescent illumination includes miniature bulbs in axial array and wrapped by a transparent material, and a core line outside the connecting wire made of soft plastic polymer. A color layer is provided outside the core line. The adoption of this structure will provide advantages of simple structure, aesthetic appearance, excellent decorative effect, rich and brilliant colors, wide range of applications, etc.

Abstract: A decorative illumination includes an illumination string and a baseplate. The baseplate is provided with laser film. The illumination string fits inside a lamphole, and the lamphole is a through hole that penetrates the baseplate and laser film. The baseplate is made form plastic film material. In addition, there is a support frame on the other side of the laser film opposite to the base plate, and the illumination string is inside the support frame and fitted in the lamphole. The illuminations in accordance with the present invention provide advantages of simple structure and aesthetic appearance that can beautify the environment and provide perfect night lighting effect, which can be used for decoration, beautifying the environment, etc.